ZBH Cash & equivalents
Cash & equivalents at Zimmer Biomet rose to $592M in fiscal 2025, the highest in the 5 years reported, from $526M in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 1136869 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$592M
FY2024 $526M
HIGH$592M FY2025
LOW$376M FY2022
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $592M | +$66M |
| FY2024 | $526M | +$110M |
| FY2023 | $416M | +$40M |
| FY2022 | $376M | $-2M |
| FY2021 | $378M | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · ZBH company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.